Objective. To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA.
Introduction
Patients with RA have an increased risk of premature death compared with the general population, mainly because of the risk of cardiovascular disease (CVD) [1, 2] . The CV risk of patients with RA is comparable to the risk of patients with type 2 diabetes mellitus (DM) [3, 4] . In addition to CV mortality, non-fatal CVD, such as myocardial infarction, cerebrovascular accidents and heart failure (HF) are more common in RA [5] .
Several determinants contribute to this increased risk, including traditional CV risk factors such as age, gender, dyslipidaemia, hypertension, smoking, obesity and DM, however, these factors only partially explain the excess CV risk [6, 7] . In addition to traditional risk factors, systemic inflammation is an important independent contributor to CV risk in RA [8, 9] .
Another explanation for the increased CV risk is that in RA (traditional), CV risk factors are undertreated, as comorbidity in patients with a chronic disease is often undertreated [10] . However, details of undertreatment in RA are sparse.
In light of the strong evidence that the CV risk in RA is of the same order of magnitude as that in type 2 DM, the Dutch cardiovascular risk management (CV-RM) guideline considers RA, like type 2 DM, an independent risk factor for CVD, for which CV-RM is necessary [11] . Evidence on (pharmacological) management of traditional CV risk factors in patients with rheumatic diseases is limited, but there are no indications that the effects of statins or antihypertensives in RA would be different than in the general population [1216] , thus CV-RM should be offered to all patients meeting the criteria set for risk reduction in the general population [17] . However, implementation of CV risk screening is still a challenge [18] . This strategy requires that all patients with RA, like patients with type 2 DM and/or CVD, are screened regularly (yearly) and CV risk managed accordingly. Since 2011, Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis (I-CaRe) has offered CV risk screening to RA patients visiting Reade, a rheumatology and rehabilitation centre in Amsterdam or Antonius Hospital in Sneek, a small city in the northern rural area of The Netherlands. The goal of this project was to assess the 10-year CV risk score and to identify treatment and undertreatment of CV risk factors in RA patients.
Methods

Study population and design
For this prospective cross-sectional cohort study, consecutive RA patients visiting the outpatient rheumatology clinic of Reade or Antonius Hospital were included. All patients were 518 years of age and diagnosed by a rheumatologist according to the 1987 ACR criteria for RA [19] . There were no other exclusion criteria. All patients were asked to sign an informed consent according to the Declaration of Helsinki before study participation and the study was approved by the local ethics committees of 
Physical examination
Specially trained and experienced research nurses performed a physical examination, including blood pressure, waist and hip circumference, height and weight. Blood pressure was measured twice (left and right) in a sitting position after 5 min of rest. Waist circumference was measured at the level of the navel and hip circumference at the level of the trochanter major of the hip bone (widest circumference). The waist:hip ratio comprised the ratio of these two circumference measurements. BMI was calculated from height and weight (clothed without shoes). RA was assessed by the 28-joint DAS (DAS28) [20] and physical functioning by the HAQ [21] .
Laboratory tests
The glucose and lipid profile, including TC, triglycerides, HDL and LDL, were assessed in fasting blood samples using the standard techniques and the atherogenic index (TC:HDL ratio) was calculated. All the above tests were performed the same day that blood was drawn.
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10-year CV risk calculation
The 10-year CV risk was calculated with the Dutch SCORE table, which uses gender, age, smoking status, SBP and the TC:HDL ratio [11] . To account for RA as a risk factor, the Dutch CV-RM guideline adds 15 years to the actual age in order to calculate 10-year CV risk. This is the same strategy that is used for the risk factor DM, since a large population-based cohort study showed that the vascular age of DM patients is 15 years greater than the vascular age of patients without DM [22] After we calculated the 10-year CV risk, we categorized patients into four groups: untreated patients with an indication for treatment, inadequately treated patients (i.e. not meeting treatment goals, e.g. SBP 4140 mmHg or LDL 42.5 mmol/l), adequately treated patients and untreated patients without an indication for treatment (i.e. no increased CV risk).
Statistical analysis
For the statistical analysis, SPSS version 22.0 (IBM, Armonk, NY, USA) was used. Patient characteristics were expressed as number and percentage [mean (S.D.)] when normally distributed or median (interquartile range) when not normally distributed. Independent t-tests were used to compare variables with a normal distribution. The Pearson chi-square test was performed on dichotomous variables. The threshold for significance was set at P < 0.05 (two-sided).
Results
Patient characteristics
From 2011 to 2015 a total of 720 consecutive RA patients underwent CV risk screening: 375 from Reade and 345 from Antonius Hospital. Patients from Antonius Hospital were more often male, older, had more prevalent CVD and more frequently were on statins and anticoagulant drugs (Table 1) . In contrast, patients from Reade had longer RA disease duration, were more often RF and ACPA positive and had more active and erosive disease. In the Reade patients, biologic treatment was more frequent and glucocorticoid treatment less frequent.
Prevalence of CVD
A history of CVD was present in 61 (8%) patients, with a slightly higher prevalence in those from Antonius Hospital compared with Reade (10 vs 7%). The following conditions were present: coronary heart disease (n = 29), HF (n = 4), cerebrovascular disease (n = 29) and peripheral artery disease (n = 6). Of the men, 13% had a history of CVD vs 7% of women. Patients with a history of CVD were significantly older; more often diagnosed with DM, hypertension and hypercholesterolaemia and more often used antidiabetic drugs, antihypertensives, statins and anticoagulants, but less often NSAIDs compared with patients without CVD. They also had a higher waist:hip ratio, lower TC, lower HDL, lower LDL and higher fasting glucose levels versus patients without CVD (Table 1) .
10-year CV risk assessment
The presence of high blood pressure and high cholesterol as measured during the CV risk screening as well as the mean 10-year CV risk score are shown in Table 2 . A total of 125 (17%) patients had a low 10-year CV risk, 153 (21%) patients had an intermediate risk and 381 (53%) patients had a high risk (Fig. 1) .
CV risk preventive treatment
In total, 500 patients (69%) had an indication to receive antihypertensives, statins or both (Fig. 2) . Of those, 199 (40%) did not receive treatment at all and 212 (42%) were inadequately treated; the other 18% were adequately treated. A total of 419 patients had an indication for statin treatment; 270 patients (64%) did not use statins despite having an indication and 149 received treatment. Fifty per cent of them reached an LDL of <2.5. A total of 378 patients had an indication for antihypertensive treatment; 123 patients (33%) did not receive treatment, while 255 used antihypertensives. Fifty per cent of them reached an SBP <140 mmHg. Fig. 3 shows the numbers and percentages per CV risk group.
Discussion
The results of this study confirm both a high prevalence of CVD risk and a very low prevalence of (adequate) preventive treatment in RA patients, not only in patients with a high CV risk (primary prevention), but also in patients who have already experienced CVD (secondary prevention). Our finding that 80% of RA patients are inadequately treated for CV risk is equal to that of another recently published Dutch study [25] . However, that cohort was established in 2006 and thus at a time when RA was not considered an independent CV risk factor. It is therefore worrisome that CV-RM implementation has not improved since then. Previously a study to establish whether lipidlowering therapy was used appropriately or not in RA patients revealed that of the 115 patients who were at 'high risk' of CVD, only 8 were receiving statins [26] . In accordance with this, a cohort study using Medicare data reported that in RA patients with indications for annual lipid testing, this was not performed in one-third of patients [27] . There are several factors that might explain this lack of improvement. First, the current CV-RM guideline was published very shortly before the present study actually started. This Strengths of this study include the size of the study population and the fact that it is a two-centre study, including patients from rural and urban areas, making it a diverse RA population. Active disease can interfere with CV risk estimation, particularly because of interference with lipid levels. In our study population, the mean disease duration was 10 years and only 2% of patients had active disease (defined as a DAS28 >5.1), therefore it is likely that CV risk was stable for most of the patients.
A limitation of this study is that we could not take into account some secondary CV risk factors, such as family history of CVD, physical activity and kidney function. These factors are, like BMI, considered CV risk increasing, which can serve as an additional reason to give CV risk prevention treatment. Thus the lack of this information could have underestimated our results. Ideally, blood pressure should be measured twice and the average used to calculate CV risk, but for practical reasons only one assessment was done. However, when blood pressure was too high we recommended reassessment by the general practitioner. Unfortunately, in this study we did not determine the reasons why RA patients were not treated or treated inadequately. This will be addressed in a followup implementation project that will be started shortly. Another study that we are currently undertaking is to investigate if yearly CV risk screening initiated by the rheumatologist improves CV-RM implementation. Two strategies will be tested: one strategy is to send high CV risk patients to their general practitioner to implement and control CV-RM, the second strategy is to send RA patients with a high CV risk to an internal specialist who implements CV-RM in the context of a specialty CV-RM clinic.
Ideally the effects of statins or antihypertensives on CV disease prevention in RA should be investigated in a large randomized trial; however, thus far no intervention trials with statins or antihypertensives and CV disease prevention in RA have been published. The TRACE RA trial was a placebo-controlled study investigating the efficacy of atorvastatin in patients with RA that was terminated early because of a low overall event rate [28] . Nevertheless, a reduction of 34% in CVD events in the statin group was demonstrated, although this did not reach statistical significance. Furthermore, data from epidemiological studies and post hoc subgroup analyses of large, secondary CV prevention trials show that the effects of statins on cholesterol levels in RA patients appear to be at least equivalent to the effects of statins in the general population [15, 29, 30] . Other studies have shown beneficial effects of angiotensin-converting enzyme (ACE) inhibitors on CV risk in RA [12] . Moreover, the effects of cardioprotective agents might be even more pronounced in RA, as the pleiotropic effects of statins, ACE inhibitors and angiotensin blockers include anti-inflammatory properties [14, 3135] . In the future, randomized controlled intervention trials are necessary to assess the actual effect of statins, ACE inhibitors and other lifestyle intervention strategies on CV risk in RA. In conclusion, our results indicate that effective strategies for adequate CV-RM are urgently needed to reduce CV risk in the RA population. 
